Skip to main content

HistoRx Raises $1.5M in Series A Financing

NEW YORK, Sept. 14 (GenomeWeb News) - HistoRx, a provider of imaging technology for tissue and tissue microarrays, has raised $1.5 million in a Series A financing round, the company said today.


HistoRx, based in New Haven, Conn., exclusively licenses the imaging technology from YaleUniversity, where it was developed by David Rimm and Robert Camp. The technology allows users to measure protein expression in subcellular compartments automatically. The company also holds an exclusive license to patient cohort databases from Yale's tissue archive containing clinical follow-up information corresponding to different types of human cancer.


HistoRx provides contract services to academic institutions and companies and licenses its technology to selected laboratories.


Navigator Technology Ventures led the investment round, which also included Genentech, Sachem Ventures, and Marnat Investments.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.